Shares of Eli Lilly & Co. LLY rallied 1.83% to $914.57 Friday, on what proved to be an all-around positive trading session ...

Will local startups give big pharma its next blockbuster drug? Eli Lilly and Pfizer are launching new biotech incubators in.

New obesity and Alzheimer’s disease treatments are keeping Eli Lilly and Company (LLY) at the forefront of equities ...

Zealand Pharma is a much smaller healthcare stock than Eli Lilly. It has multiple drug candidates with the potential to take ...

Investors shouldn't assume that all of the company's future growth is already priced into the stock's valuation.

Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the ...

Eli Lilly received FDA approval for its Alzheimer's drug on Tuesday. BMO analyst explains what Kinsula means for Lilly's ...

The FDA approved the experimental Alzheimer's drug donanemab. The drug will be sold under the brand name Kisunla.

Wall Street expectations for where Eli Lilly stock is headed this year vary considerably, but some analysts still have faith.

The US Food and Drug Administration on Tuesday approved donanemab, a monoclonal antibody designed to slow the progression of ...

Eli Lilly received FDA approval for a drug to help treat Alzheimer's on Tuesday after studies showed it could help slow the ...